U.S. approval of an expanded indication for transcatheter aortic valve replacement in patients without symptoms is among the ...

EW Investors with Losses Encouraged to Contact the Firm Before Dec. 13, 2024 DeadlineSan Francisco, California--(Newsfile Corp. - December 10, ...

Anteris Technologies today announced the launch of its initial public offering in the U.S. to advance the development of its ...

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

Advancements in medical technology have made it possible to replace heart valves using the TAVI (Transcatheter Aortic Valve ...

Image Source: Zacks Investment Research Per a Precedence Research report, the global transcatheter aortic valve replacement ...

On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for ...

The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, ...

The global structural heart devices market is witnessing remarkable growth, driven by factors such as the rising prevalence of structural heart diseases, expanding indications for transcatheter ...

Meril Life Sciences, a leading global med-tech company specializing in cardiovascular and structural heart solutions, marked ...

LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...